Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Hyphens Pharma Pte. Ltd. has 1 pending office action in the Biotechnology & Pharmaceuticals technology area. This action is assigned to 1 distinct examiner and 1 distinct art unit. The prosecution is currently focused on a single technical review. For the applicant, this means that the entire prosecution strategy is centered on a single point of contact within the USPTO. This concentration allows for a very targeted response but also means the outcome is highly dependent on the specific standards of the 1 distinct art unit.
WERTZ, ASHLEE ELIZABETH is the busiest examiner, managing 1 pending office action. This single action represents the 1 pending office action for the portfolio. The use of 1 distinct examiner and 1 distinct art unit suggests a narrow and focused interaction with the USPTO. Practitioners should prioritize understanding the examination style of WERTZ, ASHLEE ELIZABETH to effectively resolve the 1 pending office action. The focus on the Biotechnology & Pharmaceuticals area indicates a clear technical direction for the company's current intellectual property efforts at the USPTO.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Double-patenting + other | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| WERTZ, ASHLEE ELIZABETH | 1 | 52.7% | +35.6% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18843068 | COMPOSITION FOR TREATING ATOPIC DERMATITIS | WERTZ, ASHLEE ELIZABETH | — |
| Art Unit | Apps |
|---|---|
| 1612 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18843068 | COMPOSITION FOR TREATING ATOPIC DERMATITIS | WERTZ, ASHLEE ELIZABETH | 1612 | §102§103§112DP | Non-Final OA | — | Pending | Aug 30, 2024 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialHyphens Pharma Pte. Ltd. has 1 pending office actions as of October 2026, spread across 1 art units and 1 examiners.
Ashlee Elizabeth Wertz has the most, with 1 of Hyphens Pharma Pte. Ltd.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
